Kala Bio, Inc. (KALA): R&D Expense
$18.78M
Year ended 2025-12-31
+2.1%
3-year compound annual growth
+0.5%
5-year compound annual growth
+5.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.78M | -15.0% | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | $22.09M | +18.9% | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | $18.59M | +5.3% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $17.65M | +53.3% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $11.52M | -37.3% | 2023-03-03, From 2021-01-01 |
| 2020-12-31 | $18.35M | -32.7% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $27.27M | -6.9% | 2021-02-25, From 2019-01-01 |
| 2018-12-31 | $29.29M | +1.0% | 2020-02-12, From 2018-01-01 |
| 2017-12-31 | $29.01M | +15.9% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $25.03M | +119.9% | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | $11.38M | n/a | 2018-04-02, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Kala Bio, Inc. (KALA) | 2025-12-31 | $18.78M | -15.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare KALA, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗